Hos patienter, hvis CrCl var under 60 ml/ min, eller patienter med nyresygdom i sidste stadie var den gennemsnitlige eksponering for hydroxycarbamid cirka 64% højere end hos patienter med normal nyrefunktion.
In patients, whose CrCl was below 60 ml/ min or patients with end-stage renal disease the mean exposure to hydroxycarbamide was approximately 64% higher than in patients with normal renal function.